Observational Study for Dwarfism

Not currently recruiting at 32 trial locations
QT
QT
Overseen ByQED Therapeutics, Inc.
No Placebo GroupAll trial participants will receive the active study treatment (no placebo)

What You Need to Know Before You Apply

What is the purpose of this trial?

This trial aims to observe and understand the growth patterns and health challenges in children with achondroplasia, a genetic condition affecting bone growth. Researchers seek to learn more about the overall quality of life, body pain, and functional abilities of these children without administering any medication. Children aged 2.5 to less than 17 years with achondroplasia, who have not recently undergone treatments like growth hormone therapy, might be suitable candidates.

As an unphased trial, this study provides a unique opportunity to contribute to understanding achondroplasia and improving future care.

Do I need to stop my current medications to join the trial?

The trial does not specify if you need to stop taking your current medications. However, if you have been treated with growth hormone, IGF 1, or anabolic steroids in the past 6 months, or have had long-term treatment with oral corticosteroids, you may not be eligible to participate.

Why are researchers excited about this trial?

Researchers are excited about this trial because it focuses on understanding achondroplasia, a genetic condition that affects bone growth in children, through an observational study. Unlike treatments that aim to modify growth or symptoms directly, this study seeks to gather comprehensive data on the natural progression of achondroplasia. By analyzing this information, scientists hope to better understand the condition and potentially improve future treatment strategies. This approach could lead to more personalized and effective interventions for children with achondroplasia.

Who Is on the Research Team?

QT

QED Therapeutics, Inc. VP, Clinical Development

Principal Investigator

QED Therapeutics

Are You a Good Fit for This Trial?

Inclusion Criteria

Signed informed consent by study participant or parent(s) or legally authorized representative (LAR) and signed informed assent by the study participant (when applicable)
Aged 2.5 to 10 years (inclusive) at study entry
Diagnosis of ACH
See 2 more

Timeline for a Trial Participant

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Observational

Evaluation of growth, ACH-related medical complications, assessments of health-related quality of life, body pain, functional abilities, cognitive functions, and treatments of study participants

Up to 2 years

Follow-up

Participants are monitored for safety and effectiveness after the observational period

4 weeks

What Are the Treatments Tested in This Trial?

Interventions

  • Observational Study

Find a Clinic Near You

Who Is Running the Clinical Trial?

QED Therapeutics, Inc., a Bridgebio company

Lead Sponsor

QED Therapeutics, a BridgeBio company

Lead Sponsor

QED Therapeutics, Inc.

Lead Sponsor

Trials
11
Recruited
1,200+
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Terms of Service·Privacy Policy·Cookies·Security